Shares of biopharmaceutical company CytRx ( CYTR) gained 5.3% after the company said its RXi Pharmaceuticals subsidiary is licensing technology to the University of Massachusetts Medical School.

Shares were up 11 cents to $2.19 in premarket trading Thursday.

The exclusive license involves RNA interference, the company says. The university will also have the right to sublicense the so-called nanotransporter technology, which was shown to deliver RNA interference to different types of tissues in animal trials.

Financial terms were not disclosed.

If you liked this article you might like

Nationwide Egg Recall Expanded

10 Toy Fads That Have Faded

Boomers Feel Recession Burden, Blame

KFC Franchisees Want 'Fried' to Be the Focus

Heavy Weights: More Expensive, Less Effective